Show simple item record

dc.contributor.authorAlexander, M
dc.contributor.authorWolfe, R
dc.contributor.authorBall, D
dc.contributor.authorConron, M
dc.contributor.authorStirling, RG
dc.contributor.authorSolomon, B
dc.contributor.authorMacManus, M
dc.contributor.authorOfficer, A
dc.contributor.authorKarnam, S
dc.contributor.authorBurbury, K
dc.contributor.authorEvans, SM
dc.date.accessioned2020-12-21T01:21:45Z
dc.date.available2020-12-21T01:21:45Z
dc.date.issued2017-08-22
dc.identifierpii: bjc2017232
dc.identifier.citationAlexander, M., Wolfe, R., Ball, D., Conron, M., Stirling, R. G., Solomon, B., MacManus, M., Officer, A., Karnam, S., Burbury, K. & Evans, S. M. (2017). Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer. BRITISH JOURNAL OF CANCER, 117 (5), pp.744-751. https://doi.org/10.1038/bjc.2017.232.
dc.identifier.issn0007-0920
dc.identifier.urihttp://hdl.handle.net/11343/256477
dc.description.abstractINTRODUCTION: Non-small-cell lung cancer outcomes are poor but heterogeneous, even within stage groups. To improve prognostic precision we aimed to develop and validate a simple prognostic model using patient and disease variables. METHODS: Prospective registry and study data were analysed using Cox proportional hazards regression to derive a prognostic model (hospital 1, n=695), which was subsequently tested (Harrell's c-statistic for discrimination and Cox-Snell residuals for calibration) in two independent validation cohorts (hospital 2, n=479 and hospital 3, n=284). RESULTS: The derived Lung Cancer Prognostic Index (LCPI) included stage, histology, mutation status, performance status, weight loss, smoking history, respiratory comorbidity, sex, and age. Two-year overall survival rates according to LCPI in the derivation and two validation cohorts, respectively, were 84, 77, and 68% (LCPI 1: score⩽9); 61, 61, and 42% (LCPI 2: score 10-13); 33, 32, and 14% (LCPI 3: score 14-16); 7, 16, and 5% (LCPI 4: score ⩾15). Discrimination (c-statistic) was 0.74 for the derivation cohort, 0.72 and 0.71 for the two validation cohorts. CONCLUSIONS: The LCPI contributes additional prognostic information, which may be used to counsel patients, guide trial eligibility or design, or standardise mortality risk for epidemiological analyses.
dc.languageEnglish
dc.publisherNATURE PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by-nc-sa/4.0
dc.titleLung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer
dc.typeJournal Article
dc.identifier.doi10.1038/bjc.2017.232
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.affiliation.departmentMedicine (St Vincent's)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleBritish Journal of Cancer
melbourne.source.volume117
melbourne.source.issue5
melbourne.source.pages744-751
dc.rights.licenseCC BY-NC-SA
melbourne.elementsid1224227
melbourne.contributor.authorConron, Matthew
melbourne.contributor.authorBall, David
melbourne.contributor.authorSolomon, Benjamin
melbourne.contributor.authorMacManus, Michael
melbourne.contributor.authorAlexander, Marliese
dc.identifier.eissn1532-1827
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record